1. To maintain the successful retention of African-American men to the Selenium and Vitamin E Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the successful recruitment and retention of African- American men to SELECT ancillary studies. 2. To provide access to state-of-the-art cancer treatment for minority individuals by increasing minority participation in cancer treatment protocols using proven recruitment and retention strategies: 3. To raise the level of cancer prevention and control (CaP/C) opportunities offered throughout the Chicago and Northwest Indiana region by partnering with two major NCI-funded programs [Center for Population Health and Health Disparities (CPHHD) and the Patient Navigator Research Program (PNRP)] and Ingalls Health System. The UIC MB-CCOP plans to leverage these partnerships to establish a structure and framework to overcome the barriers to recruitment and retention and provide access to CaP/C trials to minority communities in this entire region. 4. To increase the awareness, understanding, and involvement of health care providers, community leaders, and local organizations in UIC MB-CCOP activities.
These aims will be achieved by an established minority clinical research headquarters within the UIC Section of Hematology/Oncology and utilizes several research bases: Cancer and Leukemia Group B (CALGB): Main Member since 1996 Southwest Oncology Group (SWOG): CCOP Expanded Access Pilot Program (1998) Eastern Cooperative Oncology Group (ECOG): Accepted July 15, 2005 (by NCI permission) Gynecologic Oncology Group (GOG) National Surgical Adjuvant Breast and Bowel Project (NSABP): STAR &P-4 The University of Michigan CCOP Research Base: CaP/C The University of Rochester CCOP Research Base: CaP/C

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA074811-14
Application #
8089551
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1997-08-15
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
14
Fiscal Year
2011
Total Cost
$600,000
Indirect Cost
Name
University of Illinois at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7

Showing the most recent 10 out of 68 publications